PT100688A - Processo para a modulacao de patologias associadas a disfuncoes de citoquinas por meio de arn de dupla cadeia - Google Patents
Processo para a modulacao de patologias associadas a disfuncoes de citoquinas por meio de arn de dupla cadeia Download PDFInfo
- Publication number
- PT100688A PT100688A PT100688A PT10068892A PT100688A PT 100688 A PT100688 A PT 100688A PT 100688 A PT100688 A PT 100688A PT 10068892 A PT10068892 A PT 10068892A PT 100688 A PT100688 A PT 100688A
- Authority
- PT
- Portugal
- Prior art keywords
- dsrna
- cells
- cytokines
- production
- cytokine
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims description 27
- 108090000695 Cytokines Proteins 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 15
- 230000008569 process Effects 0.000 title claims description 5
- 230000009977 dual effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010074338 Lymphokines Proteins 0.000 claims description 8
- 102000008072 Lymphokines Human genes 0.000 claims description 8
- 230000001594 aberrant effect Effects 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000016396 cytokine production Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 230000001133 acceleration Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000140 heteropolymer Polymers 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 235000013902 inosinic acid Nutrition 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 241000701027 Human herpesvirus 6 Species 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000002939 deleterious effect Effects 0.000 claims 1
- 230000001627 detrimental effect Effects 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000003284 homeostatic effect Effects 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 20
- 102000003390 tumor necrosis factor Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 11
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 11
- 230000037353 metabolic pathway Effects 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000004075 alteration Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Eye Examination Apparatus (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73022991A | 1991-07-16 | 1991-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT100688A true PT100688A (pt) | 1993-10-29 |
Family
ID=24934492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT100688A PT100688A (pt) | 1991-07-16 | 1992-07-15 | Processo para a modulacao de patologias associadas a disfuncoes de citoquinas por meio de arn de dupla cadeia |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0596912A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH07501787A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1068738A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2268892A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2113573A1 (cg-RX-API-DMAC7.html) |
| IE (1) | IE922145A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX9204164A (cg-RX-API-DMAC7.html) |
| PT (1) | PT100688A (cg-RX-API-DMAC7.html) |
| TW (1) | TW271398B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1993001717A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA925263B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4795744A (en) * | 1986-07-17 | 1989-01-03 | Hem Research, Inc. | Modulation of AIDS virus-related events by double-stranded RNAS |
| US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
| AU1820588A (en) * | 1987-07-17 | 1989-01-19 | Hem Research, Inc. | Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function |
| AU1820388A (en) * | 1987-07-17 | 1989-01-19 | Hem Research, Inc. | Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles |
| CA1320446C (en) * | 1988-06-20 | 1993-07-20 | William A. Carter | Modulation of lymphokine-resistant cellular states by dsrnas |
-
1992
- 1992-06-23 WO PCT/US1992/005286 patent/WO1993001717A1/en not_active Ceased
- 1992-06-23 EP EP19920914799 patent/EP0596912A4/en not_active Withdrawn
- 1992-06-23 AU AU22688/92A patent/AU2268892A/en not_active Abandoned
- 1992-06-23 JP JP5502798A patent/JPH07501787A/ja active Pending
- 1992-06-23 CA CA002113573A patent/CA2113573A1/en not_active Abandoned
- 1992-07-01 IE IE214592A patent/IE922145A1/en not_active Application Discontinuation
- 1992-07-15 MX MX9204164A patent/MX9204164A/es unknown
- 1992-07-15 PT PT100688A patent/PT100688A/pt not_active Application Discontinuation
- 1992-07-15 CN CN92105778A patent/CN1068738A/zh active Pending
- 1992-07-15 ZA ZA925263A patent/ZA925263B/xx unknown
- 1992-07-15 TW TW081105601A patent/TW271398B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0596912A1 (en) | 1994-05-18 |
| WO1993001717A1 (en) | 1993-02-04 |
| JPH07501787A (ja) | 1995-02-23 |
| AU2268892A (en) | 1993-02-23 |
| MX9204164A (es) | 1993-05-01 |
| CN1068738A (zh) | 1993-02-10 |
| CA2113573A1 (en) | 1993-02-04 |
| TW271398B (cg-RX-API-DMAC7.html) | 1996-03-01 |
| ZA925263B (en) | 1993-03-31 |
| EP0596912A4 (en) | 1994-07-27 |
| IE922145A1 (en) | 1993-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sipe et al. | Cladribine in treatment of chronic progressive multiple sclerosis | |
| CHACHOUA et al. | 9-(1, 3-Dihydroxy-2-propoxymethyl) guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome | |
| Dalakas | Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies | |
| KR0131880B1 (ko) | B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물 | |
| BR112013023151A2 (pt) | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado | |
| Michel et al. | Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases | |
| KR20040053291A (ko) | 오메가 인터페론을 이용한 질환 치료 방법 | |
| EP0347501A1 (en) | Modulation of lymphokine-resistant cellular states by dsRNAs | |
| JP3208138B2 (ja) | ウイルス性肝炎の診断及び治療 | |
| KR970007903B1 (ko) | 개인의 변형된 2'-5'-올리고아데닐레이트 합성효소 (2'-5')ran-아제 l 천연 방어 시스템을 회복시키기 위한 약학 조성물 | |
| JP2690493B2 (ja) | ウイルス感染に対するマーカー | |
| Müller et al. | Bovine leukocyte adhesion deficiency‐clinical course and laboratory findings in eight affected animals | |
| PT100688A (pt) | Processo para a modulacao de patologias associadas a disfuncoes de citoquinas por meio de arn de dupla cadeia | |
| EA010801B1 (ru) | Комбинированное применение рибавирина и бета-интерферона при демиелинизирующих заболеваниях | |
| Balci et al. | Growth parameters of Turkish children with an autoinflammatory disease before and after canakinumab treatment | |
| DE112018001364T5 (de) | Verwendung von Lambda-Interferonen bei der Behandlung von mit Adipositas zusammenhängenden Störungen und verwandten Erkrankungen | |
| AU699896B2 (en) | Means for treating autoimmune diseases and a method for the treatment thereof | |
| US6268349B1 (en) | Method for treating B19 parvovirus infections | |
| JP2001522811A (ja) | インターフェロン免疫療法 | |
| RU2003334C1 (ru) | Способ лечени больных с опухол ми | |
| JP2001516725A (ja) | 慢性Ｃ型肝炎症の処置のためのＩＦＮ−αとアマンタジンの使用 | |
| CN1564696A (zh) | 治疗和预防全身炎性反应综合症/败血症的药物组成和方法 | |
| Kurczynski et al. | Remote effect of malignancy on the nervous system in children | |
| US20230364152A1 (en) | Compositions and methods of use for infusible extracellular matrix | |
| AU729405B2 (en) | Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19930421 |
|
| FC3A | Refusal |
Effective date: 19990518 |